"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
A small number of patients have reported a transient increase in bone pain at 36 to 72 hours after injection. This is usually mild and self-limiting, and controllable with analgesics. A single patient reported chills and fever 12 hours after injection without long-term sequelae.
Additional postmarketing reactions include the following: hot flush.
Read the Metastron (strontium-89) Side Effects Center for a complete guide to possible side effects
No information provided.
Last reviewed on RxList: 1/24/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Metastron Information
Report Problems to the Food and Drug Administration
Find out what women really need.